October 13, 2021
Morphic to Participate in Jefferies IBD Therapeutics Summit
WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of…
Pharmaceuticals, Biotechnology and Life Sciences
WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of…
– IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing…
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical…
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive…
-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose…
HANGZHOU, China, Oct. 11, 2021 (GLOBE NEWSWIRE) — Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and…
4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no…
— Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD — Marked Differences in Intraocular…
Kaplan-Meier Survival: RETHYMIC Clinical Program (Efficacy Analysis Set) and Natural History Population Kaplan-Meier Survival: RETHYMIC Clinical Program (Efficacy Analysis Set)…
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics…